Monitoring iron therapy in chronic heart failure

European Journal of Heart Failure

Volumn 15, Issue 7, 2013, Pages 711-712

  Weiss, Günter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; FERRIC CARBOXYMALTOSE; NONSTEROID ANTIINFLAMMATORY AGENT;

EDITORIAL; ERYTHROCYTE; HEART FAILURE; HUMAN; INTESTINE ULCER; IRON ABSORPTION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MEAN CORPUSCULAR VOLUME; MEDICAL DECISION MAKING; OXIDATIVE STRESS; PRIORITY JOURNAL; STOMACH ULCER;

EID: 84879474818     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft096     Document Type: Editorial

References (15)

1. OkonkoDO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation toanemia, exercise capacity, and survival. J Am Coll Cardiol 2011;58:1241-1251.
2. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-1880.
3. Weiss G, Schett G. Anaemia in inflammatory rheumatic diseases. Nat Rev Rheumatol 2013; 9:205-215.
4. Niethammer M, Sieber M, von Haehling S, Anker SD, Munzel T, Horstick G, Genth-Zotz S. Inflammatory pathways in patients with heart failure and preserved ejection fraction. Int J Cardiol 2008;129:111-117.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352: 1011-1023.
6. Macdougall IC, Canaud B, de Francisco AL, Filippatos G, Ponikowski P, Silverberg D, van Veldhuisen DJ, Anker SD. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 2012;14:882-886.
7. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
8. Oexle H, Gnaiger E,Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta 1999;1413:99-107. (Pubitemid 29507549)
9. Lemieux H, Semsroth S, Antretter H, Hofer D, Gnaiger E. Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. Int J Biochem Cell Biol 2011;43:1729-1738.
10. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572-578. (Pubitemid 36871928)
11. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of ironrestricted erythropoiesis. Blood 2010;116:4754-4761.
12. Van Craenenbroeck EM, Conraads VM, Greenlaw N, Gaudesius G, Mori C, Ponikowski P, Anker SD. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Eur J Heart Fail 2013;15: 756-762.
13. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol 2013;20:222-230.
14. Montagnana M, Cervellin G, Meschi T, Lippi G. The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2012;50: 635-641.
15. van Kimmenade RR, Mohammed AA, Uthamalingam S, van der Meer P, Felker GM, Januzzi JL Jr. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail 2010;12:129-136.